On December 15, 2025, the US Food and Drug Administration (FDA) issued a press release announcing that FDA eliminated a major ...

OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced ...

The US Food and Drug Administration (FDA) released a draft guidance on April 3 providing recommendations to sponsors and testing sites on data integrity for bioavailability and bioequivalence (BA/BE) ...

Regulatory-grade evidence must reflect the true patient experience across care settings over time, supported by transparent, reproducible, and well-governed processes. John Snow Labs’ PJI platform ...

The pharmaceutical industry’s approach to data integrity has been historically manual, leveraging physical documentation and potentially unreliable paper-based ...

Echoing President Donald Trump’s call to accelerate medical innovation, Food and Drug Administration (FDA) Commissioner Marty Makary announced that the agency will no longer block companies from ...

Data integrity is an ongoing concern across all R&D organizations, no matter what part of the research lifecycle they’re navigating. These concerns extend beyond the potential for delayed timelines or ...

Ensuring data quality and harmonization transforms regulatory reporting from a compliance burden into a strategic asset, enabling confident decision-making and reducing compliance costs. Leveraging ...

FDA recently published a statement reminding medical device study sponsors and medical device manufacturers to evaluate third party’s contracted to conduct performance testing, urging independent ...

In the current digital landscape, data integrity and security have taken center stage, especially as businesses and institutions continue to depend on digital data. This reliance, however, brings its ...